InspireMD, Inc. (NSPR)

Market Cap	68.86M
Revenue (ttm)	6.82M
Net Income (ttm)	-28.24M
Shares Out	26.08M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,198
Open	2.540
Previous Close	2.570
Day's Range	2.540 - 2.705
52-Week Range	1.810 - 3.420
Beta	0.93
Analysts	Buy
Price Target	4.50 (+70.46%)
Earnings Date	Nov 12, 2024

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem le...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: NSPR
• Website: https://www.inspiremd.com

Financial Performance

In 2023, InspireMD's revenue was $6.21 million, an increase of 20.00% compared to the previous year's $5.17 million. Losses were -$19.92 million, 7.71% more than in 2022.

Analyst Forecast

According to one analyst, the rating for NSPR stock is "Buy" and the 12-month stock price forecast is $4.5.

Price Target

$4.5

(70.46% upside)

Analyst Consensus: Buy